Here’s What Analysts Are Saying About Zoetis Inc. (ZTS)

Zoetis Inc. (NYSE:ZTS) besides received a standing update from Argus connected May 27, with the steadfast downgrading the banal to Hold from Buy. It told investors successful a probe enactment that the company's banal terms underwent a melodramatic diminution of 22% successful a azygous day. It added that further losses thereafter reflected a deficiency of assurance among investors regarding the company's maturation prospects.

For reference, successful its fiscal results for fiscal Q1 2026, Zoetis Inc. (NYSE:ZTS) reported gross of $2.3 billion, up 3%, and nett income of $601 million, oregon $1.42 per diluted share, level and expanding 6%, respectively, connected a reported basis. Adjusted nett income for the 4th was $646 Million, oregon adjusted diluted EPS of $1.53.

Zoetis Inc. (NYSE:ZTS) is simply a planetary carnal wellness institution that focuses connected the discovery, development, manufacture, and commercialization of vaccines, medicines, biodevices, familial tests, diagnostic products, and precision carnal health. Its operations are divided into the United States and International segments.

While we admit the imaginable of ZTS arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 15 Stocks That Will Make You Rich successful 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Follow Insider Monkey connected Google News.